PolyPid (NASDAQ:PYPD) Earns Buy Rating from HC Wainwright

PolyPid (NASDAQ:PYPD)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $14.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 294.37% from the company’s current price.

PolyPid Price Performance

Shares of NASDAQ PYPD opened at $3.55 on Wednesday. The company has a debt-to-equity ratio of 1.95, a quick ratio of 0.95 and a current ratio of 0.95. PolyPid has a 12-month low of $2.95 and a 12-month high of $9.20. The firm’s 50-day moving average price is $3.52 and its 200-day moving average price is $4.09.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.51) by $0.26. On average, equities research analysts expect that PolyPid will post -4.39 EPS for the current year.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.